Squarepoint’s PTC Therapeutics PTCT Stock Holding History

Squarepoint’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,000	Closed	-$4.51M	–	5237
2024 Q4	$4.51M	Buy	+100,000	New	+$4.28M	﹤0.01%	1726

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's PTCT Position: Q3 2025 in Review

Squarepoint sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 181,978 shares — an estimated $8.89M sold.

Squarepoint first reported a position in PTCT in Q1 2015 and held it in 28 quarters. The position peaked at $12.3M in Q3 2024. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

Squarepoint reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
Squarepoint sold 181,978 PTC Therapeutics shares in Q3 2025, an estimated $8.89M.
Squarepoint first reported a position in PTC Therapeutics in Q1 2015 and held it in 28 quarters.
Squarepoint's PTC Therapeutics position peaked at $12.3M in Q3 2024.
293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.